BIOMAT Database Logo BIOMAT Database Logo

Progesterone-induced blocking factor (PIBF) and trophoblast invasiveness. 2011

E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
Department of Medical Microbiology and Immunology, Medical School, Pecs University, 12 Szigeti Street, H-7624 Pecs, Hungary.

Controlled trophoblast invasion is a key process during human placentation and a prerequisite for successful pregnancy. Progesterone is one of the factors to regulate trophoblast invasiveness. Progesterone-induced blocking factor (PIBF) is a progesterone-induced molecule expressed by the trophoblast, and also by tumors. The distribution of PIBF within the first-trimester decidua coincides with sites of trophoblast invasion. Another molecule that has been implicated in the control of trophoblast invasiveness is placental leptin. Leptin inhibits the secretion of progesterone by cytotrophoblast. The aim of this work was to investigate the possible interaction of PIBF and leptins in regulating trophoblast invasion. Paraffin-embedded sections from normal first-trimester placentae, partial moles, complete moles, and choriocarcinomas were reacted with PIBF, leptin, and leptin receptor specific antibodies. PIBF-deficient trophoblast cells were generated using siRNA and leptin receptor was detected on Western blot analysis. The lysates of PIBF-treated cells were used for detecting leptin expression in a protein array. PIBF was expressed in both normal first-trimester villous trophoblast and in partial mole. Compared with this, PIBF expression was markedly decreased in complete mole and absent in choriocarcinoma. Neither leptinR nor leptin were detected in partial mole, whereas both of these molecules were present in complete mole and choriocarcinoma. Leptin receptor expression was upregulated in PIBF-deficient cells, while leptin expression was decreased in PIBF-treated cells. These data suggest that PIBF affects the expression of leptin and its receptor, and that PIBF expression is inversely related to trophoblast invasiveness.

UI MeSH Term Description Entries
D010064 Embryo Implantation Endometrial implantation of EMBRYO, MAMMALIAN at the BLASTOCYST stage. Blastocyst Implantation,Decidual Cell Reaction,Implantation, Blastocyst,Nidation,Ovum Implantation,Blastocyst Implantations,Decidual Cell Reactions,Embryo Implantations,Implantation, Embryo,Implantation, Ovum,Implantations, Blastocyst,Implantations, Embryo,Implantations, Ovum,Nidations,Ovum Implantations
D010920 Placenta A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES). Placentoma, Normal,Placentome,Placentas,Placentomes
D010929 Placentation The development of the PLACENTA, a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products between mother and FETUS. The process begins at FERTILIZATION, through the development of CYTOTROPHOBLASTS and SYNCYTIOTROPHOBLASTS, the formation of CHORIONIC VILLI, to the progressive increase in BLOOD VESSELS to support the growing fetus. Hemochorial Placental Development,Hemochorial Placentation,Placental Development,Placental Development, Hemochorial,Placentation, Hemochorial
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011257 Pregnancy Proteins Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.) Placental Proteins,Proteins, Placental,Proteins, Pregnancy
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002822 Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL). Choriocarcinomas
D003656 Decidua The hormone-responsive glandular layer of ENDOMETRIUM that sloughs off at each menstrual flow (decidua menstrualis) or at the termination of pregnancy. During pregnancy, the thickest part of the decidua forms the maternal portion of the PLACENTA, thus named decidua placentalis. The thin portion of the decidua covering the rest of the embryo is the decidua capsularis. Deciduum,Deciduas

Related Publications

E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
[PIBF - Progesterone-Induced Blocking Factor].
June 2011, Zeitschrift fur Geburtshilfe und Neonatologie,
E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
Progesterone induced blocking factor (PIBF) mediates progesterone induced suppression of decidual lymphocyte cytotoxicity.
October 2002, American journal of reproductive immunology (New York, N.Y. : 1989),
E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
Oxidative stress effect on progesterone-induced blocking factor (PIBF) binding to PIBF-receptor in lymphocytes.
January 2014, Biochimica et biophysica acta,
E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
Cells isolated from human glioblastoma multiforme express progesterone-induced blocking factor (PIBF).
May 2014, Cellular and molecular neurobiology,
E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
Lymphocyte immunotherapy (LI) increases serum levels of progesterone induced blocking factor (PIBF).
January 1997, American journal of reproductive immunology (New York, N.Y. : 1989),
E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
The immunolocalization of Galectin-1 and Progesterone-Induced Blocking Factor (PIBF) in equine trophoblast: Possible roles in trophoblast invasion and the immunological protection of pregnancy.
September 2019, Placenta,
E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
Maternal serum progesterone-induced blocking factor (PIBF) in the prediction of preterm birth.
June 2015, Journal of reproductive immunology,
E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
Production and characterization of a novel monoclonal antibody against progesterone-induced blocking factor (PIBF).
July 2008, Journal of reproductive immunology,
E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
Characterisation of serum progesterone and progesterone-induced blocking factor (PIBF) levels across trimesters in healthy pregnant women.
March 2020, Scientific reports,
E Miko, and M Halasz, and B Jericevic-Mulac, and L Wicherek, and P Arck, and G Arató, and J Skret Magierlo, and D Rukavina, and J Szekeres-Bartho
The progesterone receptor antagonist mifepristone does not lower serum progesterone induced blocking factor (PIBF) in the presence of progesterone.
January 2016, Clinical and experimental obstetrics & gynecology,
Copied contents to your clipboard!